Brook Byers
Co-Founder @ Kleiner Perkins
San Francisco, United States
Brook Byers is a Series B investor at Kleiner Perkins in San Francisco focused on Health Care and Biotechnology. Brook Byers is the Board Director of Foundation Medicine Inc. He has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook was the founding President and then Chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of nine companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys, XDx, Inc He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, molecular diagnostics and genomics. Brook was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford Bio-X Advisory Council and the Stanford Eye Council. He was Co - Chair of the five year, $1.4 billion, UCSF Capital Campaign. In 2007, he was awarded the UCSF Medal as their honorary degree equivalent. He was formerly a Director of the Entrepreneurs Foundation, the California Healthcare Institute, the Asian Art Museum in San Francisco, the Stanford Graduate School of Business Advisory Council, That Many May See (UCSF) Vision Research Foundation (Chairman) and the Georgia Tech Advisory Board. Raised in Atlanta, Georgia, Brook graduated in Electrical Engineering from Georgia Tech. He received an MBA from Stanford.
- Total investments:
- 51
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Brook Byers invests in
Stages Brook Byers invests in
Countries Brook Byers invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Series A
- $3.8M–$47M
- Series B
- $15M–$71M
- Series C
- $5M–$31M
Investment Focus
Industry
- Health Care 12 (24%)
- Biotechnology 12 (24%)
- Medical 5 (10%)
- Genetics 5 (10%)
- Life Science 5 (10%)
Stage
- Series B 11 (22%)
- Series C 9 (18%)
- Series A 6 (12%)
- Series D 4 (8%)
- Series E 4 (8%)
Country
- United States 18 (35%)
- The Netherlands 1 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SpinLaunch is a space technology company pioneering a new era of scalable space infrastructure. Following years of innovation in alternative launch systems, we’re now applying that same disruptive mindset to orbit - developing Meridian Space, a ground-breaking broadband satellite constellation built for rapid deployment and low-cost globalcoverage. With backing from industry leaders, SpinLaunch is positioned to deliver a fully integrated ecosystem of launch, satellite, and connectivity services. | $71M / Series B / Sep 16, 2022 | ||
| HealthTensor develops artificially intelligent systems to automate documentation for physicians. Their technology mines the medical record for pertinent information, assists in diagnosing key conditions, and generates proper documentation.By integrating into the workflow, HealthTensor can provide trusted, evidence-backed notes directly tophysicians to save time, reduce liability, and optimize appropriate reimbursements. | $15.3M / Series A / Jun 29, 2022 | ||
| HealthRhythms develops a mental health assessment and treatment platform to measure and monitor health conditions. The company's solution utilizes deep machine learning and predictive analytics to create novel health assessments and just-in-time personalized interventions that improve the care delivery experience for patients, health plans,payers, and research organizations. | $11M / Seed / Feb 02, 2022 | ||
| Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $140M / Series B / Jan 25, 2022 | ||
| Verana Health is a digital health data company that delivers insights from unfiltered healthcare data with integrity to connect the dots between patient care and clinical research. Verana Health is exclusively entrusted by key specialty medical societies to manage data from real-world healthcare settings across more than 20,000 healthcare providersand 70 electronic health record systems. Its healthcare data ecosystem is powered by VeraQ™, a clinician-directed and AI-enhanced population health data engine that securely powers a data integrity feedback loop of nearly a half-billion raw, point-of-care health encounters. By applying advanced analytics to proprietary, curated datasets, Qdata™, Verana Health helps life sciences partners enhance evidence generation and speed clinical research that promote physicians’ quality of care and patients’ quality of life. For more information, visit www.veranahealth.com. | $150M / Series E / Jan 14, 2022 | ||
| Lightship is a provider of enterprise-level, direct-to-patient clinical research solutions. The company engages patients at home from recruitment through completion and eliminates the hurdles and inefficiencies of traditional approaches. Founded in 2018, Lightship is based in El Segundo, California. | $40M / Series C / Oct 06, 2021 | ||
| Toucan is a social-first video platform designed to mimic human interactions online. | $985K / Pre-Seed / Aug 04, 2021 | ||
| Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. | $47.1M / Series A / Mar 25, 2021 | ||
| Lightship is a provider of enterprise-level, direct-to-patient clinical research solutions. The company engages patients at home from recruitment through completion and eliminates the hurdles and inefficiencies of traditional approaches. Founded in 2018, Lightship is based in El Segundo, California. | $20M / Series B / Feb 03, 2020 | ||
| Mammoth Biosciences is harnessing the diversity of nature to power the next-generation of CRISPR products. Through the discovery and development of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth Biosciences aims to democratize disease detection with an easy and affordablepoint-of-care test that allows real-time and simultaneous detection of multiple conditions. By leveraging its internal research and development and exclusive licensing to Cas12, Cas13, and Cas14, Mammoth Biosciences can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in South San Francisco, Mammoth Biosciences is co-founded by CRISPR pioneer Jennifer Doudna and principal founders Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Mayfield, NFX, and 8VC, Decheng Capital and leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.Mammoth has also been working on developing a rapid COVID-19 test. | $45M / Series B / Jan 30, 2020 | ||
| See all 51 investments → | |||
Co-Investors
About Kleiner Perkins
Kleiner Perkins is a venture capital firm specializing in investing in early-stage, growth, and incubation companies. The firm continues that legacy, investing in founders with bold ideas that span industries and continents, partnering with them from inception to IPO and beyond to maximize the potential of their ideas. They also focus on early computer firms using their devices and programming and service companies. It also invests in the digital, life sciences, and healthcare industries.
Kleiner Perkins Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brook Byers
Co-Founder
|
|||
Charles Holloway
Vice Chairman of Board of Directors
|
|||
Ilya Fushman
Partner
|
|||
Jerry Liang
Vice President
|
|||
Kevin Compton
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Brook Byers invest in?
Brook Byers invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Series C stage. Most of the 51 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Brook Byers invest in?
Brook Byers typically joins rounds of $3.8M–$47M at Series A, $15M–$71M at Series B and $5M–$31M at Series C. These are whole funding-round sizes, not Brook Byers's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Brook Byers took part in.
How do I contact Brook Byers?
Public channels for Brook Byers include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Brook Byers last invest?
The most recent investment recorded for Brook Byers closed in Sep 2022. Shizune tracks 51 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
